CCM
SQZ

CAAS Capital Management’s SQZ Biotechnologies Company SQZ Stock Holding History

CAAS Capital Management’s Portfolio SQZ Stock Details SQZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-131,849
Closed -$1.8M – 1380
2021
Q1 		$1.8M Sell
131,849
-18,151
-12% -$369K 0.02% 623
2020
Q4 		$4.35M Buy
+150,000
New +$3.83M 0.04% 346

Other funds holding SQZ

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAAS Capital Management's SQZ Position: Q2 2021 in Review

CAAS Capital Management sold out of SQZ Biotechnologies Company (SQZ) in Q2 2021, closing a stake of 131,849 shares — an estimated $1.8M sold.

CAAS Capital Management first reported a position in SQZ in Q4 2020 and held it in 2 quarters. The position peaked at $4.35M in Q4 2020. 49 funds tracked by Wall St. Rank hold SQZ as of Q2 2021.

  • CAAS Capital Management reported no remaining SQZ Biotechnologies Company position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 131,849 SQZ Biotechnologies Company shares in Q2 2021, an estimated $1.8M.
  • CAAS Capital Management first reported a position in SQZ Biotechnologies Company in Q4 2020 and held it in 2 quarters.
  • CAAS Capital Management's SQZ Biotechnologies Company position peaked at $4.35M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held SQZ Biotechnologies Company as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.